SCHEMBL7564815

SCHEMBL7564815

CCn1c(=O)n(CC(C)(C)O)c(=O)c2c1ncn2Cc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.59
KMT2A Q03164 5/20 0.56
CNOT7 Q9UIV1 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
POLB P06746 1/20 0.55
HIF1A Q16665 1/20 0.55
MEN1 O00255 3/20 0.54
ADORA2B P29275 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
HPGD P15428 1/20 0.53
TSHR P16473 1/20 0.53
MAPK1 P28482 1/20 0.53
PDE1A P54750 1/20 0.53
PDE1B Q01064 1/20 0.53
PDE1C Q14123 1/20 0.53
KDM4E B2RXH2 2/20 0.50
USP2 O75604 1/20 0.50
LMNA P02545 1/20 0.50
HTT P42858 1/20 0.50
HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7563973 0.89 POLB (0.58) ALDH1A1KMT2ACNOT7SMN1; SMN2POLB
SCHEMBL555093 0.88 ALDH1A1 (0.65) ALDH1A1KMT2ACNOT7SMN1; SMN2POLB
SCHEMBL7565001 0.88 POLB (0.71) ALDH1A1KMT2ACNOT7SMN1; SMN2POLB
SCHEMBL7561501 0.87 POLB (0.56) ALDH1A1KMT2ACNOT7SMN1; SMN2POLB
SCHEMBL7561563 0.86 POLB (0.55) ALDH1A1KMT2ACNOT7SMN1; SMN2POLB
SCHEMBL7560381 0.83 POLB (0.53) ALDH1A1KMT2ACNOT7SMN1; SMN2POLB
SCHEMBL555718 0.81 SMN1; SMN2 (0.76) ALDH1A1KMT2ACNOT7SMN1; SMN2POLB
SCHEMBL3186736 0.81 CNOT7 (0.61) ALDH1A1KMT2ACNOT7SMN1; SMN2POLB
SCHEMBL1944712 0.80 POLB (0.70) ALDH1A1KMT2ACNOT7SMN1; SMN2POLB
SCHEMBL10815559 0.80 KMT2A (0.75) ALDH1A1KMT2ACNOT7SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020010333-A1 Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation HOECHST AKTIENGESELLSCHAFT 2002-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010333-A1 Use of xanthine derivatives for reducing the pathological hyperreactivity of eosinophilic granulocytes, novel xanthine compounds and process for their preparation EPX, XDH, MPO ALDH1A1 305/4885KMT2A 2869/4885CNOT7 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.